Monogenic Lupus

Current Rheumatology Reports

Volumn 18, Issue 12, 2016, Pages

  Lo, Mindy S ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Monogenic lupus; SLE; Systemic lupus erythematosus; Type I interferon

Indexed keywords

COMPLEMENT; DEOXYRIBONUCLEASE I; DNA; FAS LIGAND; INTERFERON; NUCLEIC ACID; PROTEIN KINASE C DELTA; DEOXYRIBONUCLEASE; DNASE1L3 PROTEIN, HUMAN; EXODEOXYRIBONUCLEASE; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; MPYS PROTEIN, HUMAN; PHOSPHOPROTEIN; PRKCD PROTEIN, HUMAN; THREE PRIME REPAIR EXONUCLEASE 1;

APOPTOSIS; CELL METABOLISM; DNA DAMAGE; DNA REPAIR; DNASE1L3 GENE; FASLG GENE; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INTERFERON PRODUCTION; INTRACELLULAR SIGNALING; MONOGENIC DISORDER; NONHUMAN; NUCLEIC ACID ANALYSIS; PRKCD GENE; REVIEW; STING GENE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREX1 GENE; GENETICS; GENOTYPE; IMMUNOLOGY; PHENOTYPE;

ENDODEOXYRIBONUCLEASES; EXODEOXYRIBONUCLEASES; FAS LIGAND PROTEIN; GENOTYPE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEMBRANE PROTEINS; PHENOTYPE; PHOSPHOPROTEINS; PROTEIN KINASE C-DELTA;

EID: 84994351086     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-016-0621-9     Document Type: Review

References (69)

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–21. doi:10.1056/NEJMra1100359.
2. Marlow AA, Peabody Jr HD, Nickel WR. Familial occurrence of systemic lupus erthematosus. JAMA. 1960;173:1641–3.
3. Moncada B, Day NK, Good RA, Windhorst DB. Lupus-erythematosus-like syndrome with a familial defect of complement. N Engl J Med. 1972;286:689–93. doi:10.1056/NEJM197203302861304.
4. Agnello V, De Bracco MM, Kunkel HG. Hereditary C2 deficiency with some manifestations of systemic lupus erythematosus. J Immunol. 1972;108:837–40.
5. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol. 2000;76:227–324.
6. Wu YL, Brookshire BP, Verani RR, Arnett FC, Yu CY. Clinical presentations and molecular basis of complement C1r deficiency in a male African-American patient with systemic lupus erythematosus. Lupus. 2011;20:1126–34. doi:10.1177/0961203311404914.
7. Amano MT et al. Genetic analysis of complement C1s deficiency associated with systemic lupus erythematosus highlights alternative splicing of normal C1s gene. Mol Immunol. 2008;45:1693–702. doi:10.1016/j.molimm.2007.09.034.
8. Wahl R et al. C2 deficiency and a lupus erythematosus-like illness: family re-evaluation. Ann Intern Med. 1979;90:717–8.
9. Kemp ME, Atkinson JP, Skanes VM, Levine RP, Chaplin DD. Deletion of C4A genes in patients with systemic lupus erythematosus. Arthritis Rheum. 1987;30:1015–22.
10. Rieux-Laucat F et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347–9.
11. Del-Rey M et al. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood. 2006;108:1306–12. doi:10.1182/blood-2006-04-015776.
12. Wu J et al. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest. 1996;98:1107–13. doi:10.1172/JCI118892.
13. Yasutomo K et al. Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet. 2001;28:313–4. doi:10.1038/91070.
14. Al-Mayouf SM et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet. 2011;43:1186–8. doi:10.1038/ng.975.
15. Lee-Kirsch MA et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med (Berl). 2007;85:531–7. doi:10.1007/s00109-007-0199-9.
16. Ellyard JI et al. Whole exome sequencing in early-onset cerebral SLE identifies a pathogenic variant in TREX1. Arthritis Rheumatol. 2014. doi:10.1002/art.38824.
17. Liu Y et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371:507–18. doi:10.1056/NEJMoa1312625.
18. Konig N et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2016. doi:10.1136/annrheumdis-2016-209841.
19. Rice GI et al. Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet. 2009;41:829–32. doi:10.1038/ng.373.
20. Ramantani G et al. Aicardi-Goutieres syndrome and systemic lupus erythematosus (SLE) in a 12-year-old boy with SAMHD1 mutations. J Child Neurol. 2011;26:1425–8. doi:10.1177/0883073811408310.
21. Rice GI et al. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat Genet. 2012;44:1243–8. doi:10.1038/ng.2414.
22. Rice GI et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet. 2014;46:503–9. doi:10.1038/ng.2933.
23. Crow YJ et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat Genet. 2006;38:910–6. doi:10.1038/ng1842.
24. Massaad MJ, et al. The base excision repair enzyme NEIL3 protects against autoimmunity. J Clin Invest. 2016; in press.
25. Briggs TA et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet. 2011;43:127–31. doi:10.1038/ng.748.
26. Belot A et al. Protein kinase cdelta deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum. 2013;65:2161–71. doi:10.1002/art.38008.
27. Walter JE et al. Impaired receptor editing and heterozygous RAG2 mutation in a patient with systemic lupus erythematosus and erosive arthritis. J Allergy Clin Immunol. 2014. doi:10.1016/j.jaci.2014.07.063.
28. Bader-Meunier B et al. Are RASopathies new monogenic predisposing conditions to the development of systemic lupus erythematosus? Case report and systematic review of the literature. Semin Arthritis Rheum. 2013;43:217–9. doi:10.1016/j.semarthrit.2013.04.009.
29. Leventopoulos G, Denayer E, Makrythanasis P, Papapolychroniou C, Fryssira H. Noonan syndrome and systemic lupus erythematosus in a patient with a novel KRAS mutation. Clin Exp Rheumatol. 2010;28:556–7.
30. Butbul Aviel Y et al. Prolidase deficiency associated with systemic lupus erythematosus (SLE): single site experience and literature review. Pediatr Rheumatol Online J. 2012;10:18. doi:10.1186/1546-0096-10-18.
31. Bryan AR, Wu EY. Complement deficiencies in systemic lupus erythematosus. Curr Allergy Asthma Rep. 2014;14:448. doi:10.1007/s11882-014-0448-2.
32. Xiang N, Li XM, Wang GS, Tao JH, Li XP. Association of Fas gene polymorphisms with systemic lupus erythematosus: a meta-analysis. Mol Biol Rep. 2013;40:407–15. doi:10.1007/s11033-012-2075-0.
33. Gulinello M, Putterman C. The MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus. J Biomed Biotechnol. 2011;2011:207504. doi:10.1155/2011/207504.
34. Napirei M et al. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet. 2000;25:177–81. doi:10.1038/76032.
35. Chitrabamrung S, Rubin RL, Tan EM. Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol Int. 1981;1:55–60.
36. Sisirak V et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell. 2016;166:88–101. doi:10.1016/j.cell.2016.05.034.
37. Lee-Kirsch MA et al. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet. 2006;79:731–7. doi:10.1086/507848.
38. Hedrich CM et al. Chilblain lupus erythematosus-a review of literature. Clin Rheumatol. 2008;27:1341. doi:10.1007/s10067-008-0975-0.
39. Tolmie JL, Shillito P, Hughes-Benzie R, Stephenson JB. The Aicardi-Goutieres syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). J Med Genet. 1995;32:881–4.
40. Crow YJ et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat Genet. 2006;38:917–20. doi:10.1038/ng1845.
41. Rice G et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet. 2007;80:811–5. doi:10.1086/513443.
42. Peschke K et al. Deregulated type I IFN response in TREX1-associated familial chilblain lupus. J Invest Dermatol. 2014;134:1456–9. doi:10.1038/jid.2013.496.
43. Lee-Kirsch MA et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007;39:1065–7. doi:10.1038/ng2091.
44. Namjou B et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 2011;12:270–9. doi:10.1038/gene.2010.73.
45. Chowdhury D et al. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol Cell. 2006;23:133–42. doi:10.1016/j.molcel.2006.06.005.
46. Yang YG, Lindahl T, Barnes DE. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell. 2007;131:873–86. doi:10.1016/j.cell.2007.10.017.
47. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008;134:587–98. doi:10.1016/j.cell.2008.06.032.
48. Peschke K et al. Loss of Trex1 in Dendritic Cells Is Sufficient To Trigger Systemic Autoimmunity. J Immunol. 2016;197:2157–66. doi:10.4049/jimmunol.1600722.
49. Gall A et al. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity. 2012;36:120–31. doi:10.1016/j.immuni.2011.11.018.
50. Crow YJ et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A. 2015;167A:296–312. doi:10.1002/ajmg.a.36887.
51. Pizzi S et al. Reduction of hRNase H2 activity in Aicardi-Goutieres syndrome cells leads to replication stress and genome instability. Hum Mol Genet. 2015;24:649–58. doi:10.1093/hmg/ddu485.
52. Kono M et al. Dyschromatosis Symmetrica Hereditaria and Aicardi-Goutieres Syndrome 6 Are Phenotypic Variants Caused by ADAR1 Mutations. J Invest Dermatol. 2016;136:875–8. doi:10.1016/j.jid.2015.12.034.
53. Rutsch F et al. A specific IFIH1 gain-of-function mutation causes Singleton-Merten syndrome. Am J Hum Genet. 2015;96:275–82. doi:10.1016/j.ajhg.2014.12.014.
54. Ballana E, Este JA. SAMHD1: at the crossroads of cell proliferation, immune responses, and virus restriction. Trends Microbiol. 2015;23:680–92. doi:10.1016/j.tim.2015.08.002.
55. An J et al. Tartrate-Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus Erythematosus. Arthritis Rheumatol. 2016. doi:10.1002/art.39810.
56. Mecklenbrauker I, Saijo K, Zheng NY, Leitges M, Tarakhovsky A. Protein kinase Cdelta controls self-antigen-induced B-cell tolerance. Nature. 2002;416:860–5. doi:10.1038/416860a.
57. Walter JE et al. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest. 2015;125:4135–48. doi:10.1172/JCI80477.
58. Notarangelo LD, Kim MS, Walter JE, Lee YN. Human RAG mutations: biochemistry and clinical implications. Nat Rev Immunol. 2016;16:234–46. doi:10.1038/nri.2016.28.
59. Lisbona MP, Moreno M, Orellana C, Gratacos J, Larrosa M. Noonan syndrome associated with systemic lupus erythematosus. Lupus. 2009;18:267–9. doi:10.1177/0961203308094996.
60. Martin DM, Gencyuz CF, Petty EM. Systemic lupus erythematosus in a man with Noonan syndrome. Am J Med Genet. 2001;102:59–62.
61. Mor A, Philips MR, Pillinger MH. The role of Ras signaling in lupus T lymphocytes: biology and pathogenesis. Clin Immunol. 2007;125:215–23. doi:10.1016/j.clim.2007.08.008.
62. Deng C et al. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum. 2001;44:397–407. doi:10.1002/1529-0131(200102)44:2<397::AID-ANR59>3.0.CO;2-N.
63. Coit P et al. Epigenome profiling reveals significant DNA demethylation of interferon signature genes in lupus neutrophils. J Autoimmun. 2015;58:59–66. doi:10.1016/j.jaut.2015.01.004.
64. Klar A et al. Prolidase deficiency: it looks like systemic lupus erythematosus but it is not. Eur J Pediatr. 2010;169:727–32. doi:10.1007/s00431-009-1102-1.
65. Lubick KJ et al. Flavivirus Antagonism of Type I Interferon Signaling Reveals Prolidase as a Regulator of IFNAR1 Surface Expression. Cell Host Microbe. 2015;18:61–74. doi:10.1016/j.chom.2015.06.007.
66. Aoki M et al. Lysinuric protein intolerance in siblings: complication of systemic lupus erythematosus in the elder sister. Eur J Pediatr. 2001;160:522–3.
67. De Ravin SS et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol. 2008;122:1097–103. doi:10.1016/j.jaci.2008.07.050.
68. Schepp J et al. Deficiency of Adenosine Deaminase 2 Causes Antibody Deficiency. J Clin Immunol. 2016;36:179–86. doi:10.1007/s10875-016-0245-x.
69. Manolio TA et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747–53. doi:10.1038/nature08494.